The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It's an interesting point in an ideal scenario but I think this is a misunderstanding or mischaracterisation of what is happening. Duration of cohort is dependent on participant availability, dropout, recruitment etc. One can not assume the trial is running perfectly, with all recruits available dosed simultaneously and regularly from day 0 and no hiccups along the way. When a person (assume in at day 0) is done with their participation, meaning no more dosing for them, the trial goes on in a staggered way until they meet the initially set out end point Otherwise the entire P1A would have been done months ago.
Either way they are getting closer with every day that goes by and we are all understandably anticipating a fantastic readout, PR, science day with bells and whistles and all that jazz.
GLA Ray
I'd advise holders to be cautious and not to forward sell shares they **think** they got allocated. Unless they want to buy them back at (currently) ~39% premium. I asked for x10 what I was entitled to, but will be amazed if I get x2.
GLA LTH
Ray
If people hadn’t hyped up this presentation they probably would not even have RNSed it. Presenting the same or sinilar findings repeatedly at conferences or invited talks is very common for scientific companies. Odds are that nobody on here will even get to witness the presentation as it seems to be behind a paywall like with most scientific meetings/ and conferences. We’re close to the end of P1a, but don’t let that make everybody desperate. Also just because C3 lasted a certain number of days and was shorter than C2 which was shorter than C1, doesn’t guarantee C4 will be the exact same. They’ll get there, but don’t rely on possibly unrealistic expectations of timelines based on conjecture.
Gla
Maybe we don’t need to find the MTD, the point is they can just do multiple/extended cycles that hit the target and no/reduced collateral damage… So the whole MTD argument is a bit moot. We know Dox kills cells extremely well at the doses used in clinic. To me, they won’t keep looking for MTD, you don’t just change the trial design mid-way. Especially as current ava6000 dose is already exceeding usual Dox dosage?
To me this part is telling
“enabling further treament cycles to be administered.”
Gla
Something that may not have been picked up yet, but cutting the ribbon was "Lord James O’Shaughnessy – one of the UK’s leading policy advisors, and a driving force for life sciences within industry and at the highest levels of government. Lord O’Shaughnessy has served as a Minister at the Department for Health and Social Care, as Director of the No. 10 Policy Unit, and as an advisor to DHSC Ministers throughout the COVID pandemic."
Seems like a good person to have on their side.
Formal opening of Avacta Therapeutics’ new headquarters at Scale Space
https://www.whitecityinnovationdistrict.org.uk/avacta-celebrates-formal-opening-at-scale-space/